The successful commercial launch of PALSONIFY represents a major milestone, but the company's significant cash burn ($326.2 million in 2025) despite new revenue suggests ongoing dependence on capital markets. Traders should monitor quarterly revenue growth trends and cash burn rate as key indicators of commercial execution and sustainability.
Price Chart
Executive Summary
Crinetics Pharmaceuticals reported its first commercial revenue from PALSONIFY, generating $5.4 million in net product revenue in Q4 2025 following FDA approval. The company also announced a positive CHMP opinion for European approval, initiated multiple Phase 3 trials, and raised $380 million in a public offering, ending 2025 with $1.0 billion in cash. Despite strong commercial launch momentum, the company reported a significant net loss of $465.3 million for the year.
Key Financial Metrics
Key Facts
- PALSONIFY generated $5.4 million in net product revenue in Q4 2025, its first full quarter on the market after FDA approval
- Company secured positive CHMP opinion for PALSONIFY in Europe, with EC decision pending
- Initiated three pivotal Phase 3 trials: CAREFNDR (paltusotine for carcinoid syndrome), CALM-CAH, and BALANCE-CAH (atumelnant for CAH)
- Raised $380 million in January 2026 public offering, bringing cash position to $1.4 billion post-offering
- Ended 2025 with $1.0 billion in cash, cash equivalents, and investment securities
- Reported net loss of $465.3 million for full year 2025 on revenue of $7.7 million
Financial Impact
Revenue grew from $1.0 million in 2024 to $7.7 million in 2025, but R&D and SG&A expenses increased significantly to $332.1 million and $191.3 million respectively, resulting in a $465.3 million net loss
Segment Breakdown
| Segment | Revenue |
|---|---|
| PALSONIFY | $5.4M |
Risk Factors
- High cash burn rate continues despite commercial revenue, with 2026 operating expense guidance of $600-$650 million
- European approval not yet guaranteed despite positive CHMP opinion
- Pipeline development risks across multiple Phase 3 programs with substantial funding requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001658247-26-000011 |
| Document: crnx-20260226.htm | 0001658247-26-000011 |
| Document: 0001658247-26-000011-index-headers.html | 0001658247-26-000011 |
| Document: 0001658247-26-000011-index.html | 0001658247-26-000011 |
| Document: 0001658247-26-000011.txt | 0001658247-26-000011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access